Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,469.30 +21.43 (+0.39%) Dow
39,112.16 -299.05 (-0.76%) Nasdaq
17,717.65 +220.84 (+1.26%) Bitcoin USD
61,382.62 +235.63 (+0.39%) CMC Crypto 200
1,274.81 -8.97 (-0.70%)
ENDRA Life Sciences Inc. (NDRA)
Pre-market:
| Previous close | 0.1106 |
| Open | 0.1079 |
| Bid | 0.1038 x 3400 |
| Ask | 0.1058 x 2700 |
| Day's range | 0.1012 - 0.1110 |
| 52-week range | 0.0690 - 2.7900 |
| Volume | |
| Avg. volume | 18,324,261 |
| Market cap | 7.245M |
| Beta (5Y monthly) | 1.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.9100 |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.00 |
- Business Wire
ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering
ANN ARBOR, Mich., June 04, 2024--ENDRA Life Sciences Inc. (Nasdaq: NDRA) ("ENDRA" or the "Company"), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced today that it has priced a public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting placement agent fees and other estimated expenses payable by the Company. The offering is a best-efforts offering, with no minimum amount of securities required to be sold.
- Business Wire
ENDRA Provides Update Following In-person Meeting with FDA
ANN ARBOR, Mich., May 20, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced that it has completed what it considers to be a highly informative pre-submission meeting with the U.S. Food and Drug Administration (FDA) related to the clinical trial design of the TAEUS liver device in support of its U.S. De Novo filing.
- GuruFocus.com
ENDRA Life Sciences Inc (NDRA) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
Discover how ENDRA Life Sciences Inc navigates its financial landscape and strategic milestones amidst ongoing challenges.
